MAPT (Ab-235) Antibody

What is MAPT (Ab-235) antibody and what epitope does it recognize?

MAPT (Ab-235) antibody recognizes the microtubule-associated protein tau specifically at the phosphorylation site Ser235. The target protein, also known as Tau, PHF-Tau, pTau, DDPAC, or FTDP-17, is approximately 78.9 kilodaltons in mass and serves as a documented neurodegenerative marker . This antibody is particularly valuable for investigating tau phosphorylation states associated with pathological conditions such as Alzheimer's disease and other tauopathies.

What are the key applications for MAPT (Ab-235) antibody in neurodegenerative research?

The MAPT (Ab-235) antibody is primarily employed in the following experimental applications:

The antibody shows consistent reactivity with human, mouse, and rat samples, making it versatile for comparative studies across species models of neurodegenerative disorders .

How should I optimize Western blot protocols when using MAPT (Ab-235) antibody?

For optimal Western blot results with MAPT (Ab-235) antibody:

• Sample preparation: Use fresh brain tissue lysates homogenized in lysis buffer containing protease and phosphatase inhibitors to preserve phosphorylation states

• Blocking: Implement 5% non-fat dry milk in TBST for reducing background signal

• Incubation conditions: Use a 1:500-1:1000 dilution in primary antibody buffer at 4°C overnight

• Controls: Include both phosphorylated and non-phosphorylated tau samples to verify specificity

• Loading control: GAPDH antibody is recommended for normalization

• Detection system: Fluorescent-labeled secondary antibodies provide superior quantitative results compared to chemiluminescence

When analyzing results, note that tau appears as multiple bands due to different isoforms and phosphorylation states, typically around 48, 62, and 78 kDa .

What validation steps should be performed when implementing MAPT (Ab-235) antibody in a new experimental paradigm?

When introducing MAPT (Ab-235) antibody into a new experimental setup, proper validation is essential:

• Specificity testing:

  • Perform side-by-side comparison with established anti-tau antibodies

  • Use competitive peptide blocking with both phosphorylated and non-phosphorylated peptides

  • Include phosphatase-treated samples as controls to confirm phospho-specificity

• Reproducibility assessment:

  • Perform technical replicates across multiple sample preparations

  • Test antibody performance across different lots if available

• Cross-reactivity evaluation:

  • Verify species cross-reactivity if working with non-human models

  • Assess potential cross-reactivity with similar phospho-epitopes on other proteins

This validation process ensures reliable and interpretable results in subsequent experiments.

How does MAPT (Ab-235) antibody compare to other phospho-tau antibodies in distinguishing different tauopathies?

Different phospho-tau antibodies show varied efficacy in distinguishing tauopathies:

The MAPT (Ab-235) antibody is particularly valuable for early detection of pathological changes, as phosphorylation at Ser235 often precedes extensive tangle formation. For comprehensive tauopathy profiling, researchers should consider employing multiple phospho-specific antibodies targeting different epitopes to capture the complete phosphorylation profile .

What are the technical challenges when using MAPT (Ab-235) antibody for immunoprecipitation of tau from brain homogenates?

Immunoprecipitation of tau using MAPT (Ab-235) antibody presents several technical challenges:

• Epitope accessibility: The phospho-Ser235 site may be partially masked in aggregated tau forms, requiring optimization of extraction methods

• Antibody concentration: Typically requires higher concentrations (5-10 μg) than used for Western blotting

• Buffer composition: Phosphatase inhibitors are critical to maintain the phosphorylation state during extraction and immunoprecipitation procedures

• Cross-linking considerations: If using bead-conjugated systems, ensure antibody orientation preserves epitope recognition

• Pre-clearing requirements: Brain homogenates often require extensive pre-clearing to reduce non-specific binding

To overcome these challenges, researchers should first validate the IP protocol with recombinant phosphorylated tau before applying it to complex brain samples.

What factors might contribute to inconsistent results when using MAPT (Ab-235) antibody in Western blots?

Several factors can contribute to inconsistent results with MAPT (Ab-235) antibody:

• Sample preparation issues:

  • Inadequate phosphatase inhibition leading to dephosphorylation

  • Post-mortem delay affecting phosphorylation profile in tissue samples

  • Freeze-thaw cycles degrading phospho-epitopes

• Technical parameters:

  • SDS-PAGE conditions affecting tau migration patterns

  • Transfer efficiency variations for high molecular weight tau aggregates

  • Inconsistent blocking procedures leading to background variation

• Antibody-specific considerations:

  • Lot-to-lot variations in antibody performance

  • Storage conditions affecting antibody stability

  • Dilution inaccuracies impacting signal intensity

To address these issues, maintain strict standardization of sample handling protocols, include positive controls in each experiment, and validate new antibody lots against previous results.

How should I design experiments to distinguish between physiological and pathological tau phosphorylation at Ser235?

Distinguishing physiological from pathological tau phosphorylation requires carefully designed experiments:

• Control selection:

  • Age-matched controls are essential as phosphorylation patterns change with aging

  • Include brain regions differentially affected in tauopathies

• Quantitative approaches:

  • Normalize phospho-Ser235 signal to total tau levels

  • Consider ratio analysis of multiple phosphorylation sites

• Sequential extraction protocols:

  • Compare soluble vs. insoluble fractions to identify aggregation-associated phosphorylation

  • Use differential detergent extractions (e.g., Triton X-100 vs. sarkosyl-insoluble preparations)

• Correlative analyses:

  • Pair Western blot results with immunohistochemistry to assess cellular distribution

  • Correlate phosphorylation levels with functional or clinical measures

This comprehensive approach helps differentiate between normal tau regulation and pathological hyperphosphorylation.

How can MAPT (Ab-235) antibody be utilized in novel therapeutic development research?

MAPT (Ab-235) antibody has valuable applications in therapeutic development:

• Target validation studies:

  • Use to verify the presence and accessibility of pSer235 epitope in pathological samples

  • Employ in competition assays to screen candidate therapeutic antibodies

• Mechanistic investigations:

  • Assess the effects of experimental compounds on tau phosphorylation status

  • Monitor changes in pSer235 levels during therapeutic interventions

• Biomarker development:

  • Evaluate pSer235 tau as a potential biomarker for treatment response

  • Develop quantitative assays for monitoring disease progression

• Therapeutic antibody design:

  • Use structural information from epitope binding to inform therapeutic antibody engineering

  • Compare effectiveness against antibodies targeting other phospho-epitopes

Recent clinical trial failures of N-terminal anti-tau antibodies highlight the importance of epitope selection in therapeutic development, suggesting mid-region or microtubule-binding region antibodies may have greater potential for preventing pathological tau propagation .

What insights can structural studies with MAPT (Ab-235) antibody provide about phospho-epitope recognition mechanisms?

Structural studies with phospho-specific antibodies like MAPT (Ab-235) provide crucial insights:

• Recognition mechanisms:

  • High-resolution structures reveal "bowl-like" conformations in CDR regions that specifically interact with phosphate groups

  • Disulfide-constrained CDR loops may mediate peptide recognition beyond the phospho-site

• Specificity determinants:

  • Hydrogen bond networks provide the structural basis for ultra-specific recognition of phospho-epitopes

  • Understanding these interactions can inform the design of more specific antibodies

• Co-crystal structures:

  • Analysis at resolutions of ~1.9 Å allows detailed mapping of antibody-epitope interactions

  • Such structures reveal how antibodies distinguish between closely related phosphorylation sites

These structural insights not only enhance our understanding of antibody-epitope recognition but also facilitate the rational design of next-generation therapeutic antibodies with optimized binding properties.

How might MAPT (Ab-235) antibody be adapted for emerging single-cell analysis techniques?

Adaptation of MAPT (Ab-235) antibody for single-cell techniques presents promising opportunities:

• Single-cell proteomics:

  • Conjugation with mass cytometry labels (e.g., metal isotopes) for CyTOF analysis

  • Integration into microfluidic antibody capture platforms for single-cell western blotting

• Spatial transcriptomics correlation:

  • Pairing with in situ sequencing techniques to correlate pSer235 tau with gene expression profiles

  • Development of proximity ligation assays to detect tau-protein interactions at single-cell resolution

• Live-cell imaging applications:

  • Conversion to smaller formats (e.g., single-chain variable fragments)

  • Adaptation for intrabody applications through cell-penetrating peptide conjugation

• Single-molecule detection:

  • Incorporation into super-resolution microscopy protocols

  • Application in single-molecule pull-down assays for studying tau conformation states

These adaptations would enable unprecedented insights into the heterogeneity of tau pathology at the single-cell level, potentially revealing cell-type specific vulnerabilities in tauopathies.

What are the prospects for developing a comprehensive database of tau epitope-specific antibodies and their research applications?

The development of a comprehensive tau antibody database would significantly advance the field:

• Database structure considerations:

  • Organization similar to the Dengue virus antibody database with sections for antibody characteristics, activity, and epitope information

  • Inclusion of standardized validation metrics for comparing antibody performance

• Key content components:

  • Detailed epitope mapping information with at least domain-level resolution

  • Comprehensive binding and neutralization data

  • Host organism and immune history information

  • Selection criteria used to isolate or develop each antibody

• Practical research applications:

  • Facilitation of epitope propensity analyses to identify immunodominant regions

  • Computational prediction of structural homology and antigen binding using position-specific structure-scoring matrices (P3SM)

  • Standardization of reporting to enhance reproducibility across laboratories

• Implementation challenges:

  • Requiring consistent validation across diverse experimental systems

  • Maintaining updated information as new antibodies are developed

  • Establishing community consensus on validation standards